Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the ...

ASH: Extended apixaban cuts recurrent VTE risk Taking apixaban for an additional year after standard treatment reduced recurrent venous thromboembolism without increasing major bleeding. HealthDay ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

For people taking popular blood thinners after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests. The ...

Patients with cancer and VTE are at risk for VTE recurrence, and there are limited data on appropriate and effective anticoagulation regimens beyond 6 months. New research findings are summarized in a ...